Medullary Thyroid Carcinoma: Why Is Specialization Mandatory?

Overview

Journal Visc Med

Date 2019 Jan 25

PMID 30675485

Citations 4

Authors

Theresia Weber

Affiliations

Soon will be listed here.

Abstract

Medullary thyroid carcinoma (MTC) represents a distinct form of thyroid cancer with a potentially aggressive behavior, early lymph node metastases, and sporadic as well as hereditary forms. Only surgery with total thyroidectomy and lymph node dissection is able to achieve biochemical cure. Due to the uncommon nature of MTC, a specialization in endocrine surgery for diagnosis as well as therapy of MTC seem to be mandatory for a successful treatment. Knowledge of genotype-phenotype correlations for hereditary forms or routine calcitonin screening for sporadic forms is important to analyze preoperative findings and plan surgical procedures. Postoperative follow-up depends on biochemical cure or monitoring for patients with elevated calcitonin levels.

Citing Articles

The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review.

Muntean C, Solomon A, Cipaian R, Vonica R, Butuca A, Gaborean V J Clin Med. 2025; 14(2.

PMID: 39860342 PMC: 11765571. DOI: 10.3390/jcm14020338.

Holomics and Artificial Intelligence-Driven Precision Oncology for Medullary Thyroid Carcinoma: Addressing Challenges of a Rare and Aggressive Disease.

Luvhengo T, Moeng M, Sishuba N, Makgoka M, Jonas L, Mamathuntsha T Cancers (Basel). 2024; 16(20).

PMID: 39456563 PMC: 11505703. DOI: 10.3390/cancers16203469.

Management of lymph nodes in medullary thyroid carcinoma: A review.

Shaghaghi A, Salari A, Jalaeefar A, Shirkhoda M Ann Med Surg (Lond). 2022; 81:104538.

PMID: 36147070 PMC: 9486732. DOI: 10.1016/j.amsu.2022.104538.

Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.

Jiang M, Shi X, Zhu H, Wei W, Li J Med Sci Monit. 2019; 25:5170-5180.

PMID: 31298226 PMC: 6642674. DOI: 10.12659/MSM.916815.

Frontiers in Surgical Evolution: A Festschrift Honoring Ernst Klar.

Alsfasser G Visc Med. 2019; 34(6):411.

PMID: 30675483 PMC: 6341315. DOI: 10.1159/000495226.

References

Moley J, DeBenedetti M . Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999; 229(6):880-7; discussion 887-8. PMC: 1420836. DOI: 10.1097/00000658-199906000-00016. View

Schilling T, Burck J, Sinn H, Clemens A, Otto H, Hoppner W . Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001; 95(1):62-6. DOI: 10.1002/1097-0215(20010120)95:1<62::aid-ijc1011>3.0.co;2-1. View

Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R . Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001; 130(6):1044-9. DOI: 10.1067/msy.2001.118380a. View

HAZARD J, HAWK W, CRILE Jr G . Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959; 19(1):152-61. DOI: 10.1210/jcem-19-1-152. View

Barbet J, Campion L, Kraeber-Bodere F, Chatal J . Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005; 90(11):6077-84. DOI: 10.1210/jc.2005-0044. View

Koperek O, Scheuba C, Cherenko M, Neuhold N, De Micco C, Schmid K . Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathology. 2008; 52(5):623-30. DOI: 10.1111/j.1365-2559.2008.03002.x. View

Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H . Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010; 20(5):527-33. DOI: 10.1089/thy.2009.0342. View

Moley J . Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010; 8(5):549-56. DOI: 10.6004/jnccn.2010.0042. View

Chambon G, Alovisetti C, Idoux-Louche C, Reynaud C, Rodier M, Guedj A . The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab. 2010; 96(1):75-81. DOI: 10.1210/jc.2010-0162. View

10.

Dralle H, Musholt T, Schabram J, Steinmuller T, Frilling A, Simon D . German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013; 398(3):347-75. DOI: 10.1007/s00423-013-1057-6. View

11.

Kwon H, Kim W, Choi Y, Jang E, Jeon M, Song D . A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2014; 82(4):598-603. DOI: 10.1111/cen.12562. View

12.

Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S . Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf). 2014; 82(2):280-5. DOI: 10.1111/cen.12563. View

13.

Rowland K, Jin L, Moley J . Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol. 2014; 22(1):96-102. DOI: 10.1245/s10434-014-4102-y. View

14.

Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6):567-610. PMC: 4490627. DOI: 10.1089/thy.2014.0335. View

15.

Jung K, Kim S, Yoo W, Kim B, Lee Y, Kim K . Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years. Clin Endocrinol (Oxf). 2015; 84(4):587-97. DOI: 10.1111/cen.12852. View

16.

Machens A, Dralle H . Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol. 2016; 175(3):219-28. DOI: 10.1530/EJE-16-0325. View

17.

Romero-Lluch A, Cuenca-Cuenca J, Guerrero-Vazquez R, Martinez-Ortega A, Tirado-Hospital J, Borrego-Dorado I . Diagnostic utility of PET/CT with F-DOPA and F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging. 2017; 44(12):2004-2013. DOI: 10.1007/s00259-017-3759-4. View

18.

Allelein S, Ehlers M, Morneau C, Schwartz K, Goretzki P, Seppel T . Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Horm Metab Res. 2017; 50(1):23-28. DOI: 10.1055/s-0043-122237. View

19.

Mathiesen J, Kroustrup J, Vestergaard P, Stochholm K, Poulsen P, Rasmussen A . Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a nationwide study. Endocr Connect. 2018; 7(6):829-839. PMC: 6000757. DOI: 10.1530/EC-18-0157. View

20.

Musholt T, Bockisch A, Clerici T, Dotzenrath C, Dralle H, Goretzki P . [Update of the S2k guidelines : Surgical treatment of benign thyroid diseases]. Chirurg. 2018; 89(9):699-709. DOI: 10.1007/s00104-018-0653-y. View